BR112020017184A2 - Disruptores de dímero egfr e uso dos mesmos - Google Patents
Disruptores de dímero egfr e uso dos mesmos Download PDFInfo
- Publication number
- BR112020017184A2 BR112020017184A2 BR112020017184-0A BR112020017184A BR112020017184A2 BR 112020017184 A2 BR112020017184 A2 BR 112020017184A2 BR 112020017184 A BR112020017184 A BR 112020017184A BR 112020017184 A2 BR112020017184 A2 BR 112020017184A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- salt according
- fact
- egfr
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862634452P | 2018-02-23 | 2018-02-23 | |
| US62/634,452 | 2018-02-23 | ||
| PCT/US2019/019391 WO2019165358A1 (en) | 2018-02-23 | 2019-02-25 | Egfr dimer disruptors and use of the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020017184A2 true BR112020017184A2 (pt) | 2020-12-22 |
Family
ID=67688515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020017184-0A BR112020017184A2 (pt) | 2018-02-23 | 2019-02-25 | Disruptores de dímero egfr e uso dos mesmos |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11358965B2 (https=) |
| EP (1) | EP3755323A4 (https=) |
| JP (2) | JP7497046B2 (https=) |
| KR (1) | KR102748047B1 (https=) |
| CN (1) | CN111886009A (https=) |
| AU (1) | AU2019223168B2 (https=) |
| BR (1) | BR112020017184A2 (https=) |
| CA (1) | CA3091834A1 (https=) |
| EA (1) | EA202092000A1 (https=) |
| MX (1) | MX2020008767A (https=) |
| WO (1) | WO2019165358A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3091834A1 (en) * | 2018-02-23 | 2019-08-29 | The Regents Of The University Of Michigan | Egfr dimer disruptors and use of the same |
| CN114286676A (zh) * | 2019-08-22 | 2022-04-05 | 密歇根大学董事会 | 治疗kras相关癌症的方法 |
| CA3172812A1 (en) * | 2020-03-05 | 2021-09-10 | The Regents Of The University Of Michigan | Inhibitors of egfr, kras, braf, and other targets and use of the same |
| MX2022010977A (es) * | 2020-03-05 | 2022-12-02 | Univ Michigan Regents | Inhibidores de egfr, kras, braf y otros objetivos y uso de los mismos. |
| IL301532A (en) | 2020-09-23 | 2023-05-01 | Scorpion Therapeutics Inc | History Pyrrolo[2,3-C]pyridin-4-one is useful in cancer treatment |
| WO2022072632A1 (en) | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Bicyclic compounds for use in the treatment cancer |
| WO2022072645A2 (en) | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| TW202229282A (zh) | 2020-09-30 | 2022-08-01 | 美商史考皮恩治療有限公司 | 治療癌症之方法 |
| BR112023006531A2 (pt) | 2020-10-09 | 2023-10-03 | Scorpion Therapeutics Inc | Inibidores heterocílicos de egfr e/ou her2, para uso no tratamento de câncer |
| EP4225304B1 (en) * | 2020-10-12 | 2025-12-17 | The Regents of The University of Michigan | Synthesis of egfr modulators |
| WO2022077154A1 (en) * | 2020-10-12 | 2022-04-21 | The Regents Of The University Of Michigan | Synthesis of egfr modulators |
| WO2022094271A1 (en) | 2020-10-30 | 2022-05-05 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| WO2022098992A1 (en) | 2020-11-05 | 2022-05-12 | Scorpion Therapeutics, Inc. | Use of macrocyclic compounds in methods of treating cancer |
| WO2022197913A1 (en) | 2021-03-18 | 2022-09-22 | Scorpion Therapeutics, Inc. | Bicyclic derivatives which can be used to treat cancer |
| EP4323356A1 (en) | 2021-04-13 | 2024-02-21 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
| WO2023173083A1 (en) | 2022-03-11 | 2023-09-14 | Scorpion Therapeutics, Inc. | Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer |
| CN121909190A (zh) | 2023-06-08 | 2026-04-21 | 安塔列斯疗法股份有限公司 | 1,5-二氢-4H-吡咯并[3,2-c]吡啶-4-酮用于癌症治疗 |
| CN121712773A (zh) | 2023-06-08 | 2026-03-20 | 安塔列斯疗法股份有限公司 | 1,5-二氢-4h-吡咯并[3,2-c]吡啶-4-酮用于癌症治疗 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3547977A (en) | 1967-10-27 | 1970-12-15 | Velsicol Chemical Corp | Novel carbanilates |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| CA2709784A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2012087943A2 (en) | 2010-12-20 | 2012-06-28 | The Regents Of The University Of Michigan | Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction |
| WO2014176475A2 (en) * | 2013-04-26 | 2014-10-30 | The Regents Of The University Of Michigan | Egfr inhibitors and uses thereof |
| US9499551B2 (en) * | 2014-01-24 | 2016-11-22 | Confluence Life Sciences, Inc. | Substituted pyrrolo[2,3-b]pyridines for treating cancer or inflammatory diseases |
| CN113563332B (zh) * | 2014-12-23 | 2024-12-17 | 达纳－法伯癌症研究所公司 | 作为egfr抑制剂的新的嘧啶和治疗病症的方法 |
| CA3091834A1 (en) | 2018-02-23 | 2019-08-29 | The Regents Of The University Of Michigan | Egfr dimer disruptors and use of the same |
-
2019
- 2019-02-25 CA CA3091834A patent/CA3091834A1/en active Pending
- 2019-02-25 EP EP19757355.3A patent/EP3755323A4/en active Pending
- 2019-02-25 MX MX2020008767A patent/MX2020008767A/es unknown
- 2019-02-25 WO PCT/US2019/019391 patent/WO2019165358A1/en not_active Ceased
- 2019-02-25 US US16/970,655 patent/US11358965B2/en active Active
- 2019-02-25 KR KR1020207027147A patent/KR102748047B1/ko active Active
- 2019-02-25 EA EA202092000A patent/EA202092000A1/ru unknown
- 2019-02-25 CN CN201980020234.3A patent/CN111886009A/zh active Pending
- 2019-02-25 JP JP2020544510A patent/JP7497046B2/ja active Active
- 2019-02-25 AU AU2019223168A patent/AU2019223168B2/en active Active
- 2019-02-25 BR BR112020017184-0A patent/BR112020017184A2/pt unknown
-
2022
- 2022-05-09 US US17/739,358 patent/US11999731B2/en active Active
-
2024
- 2024-01-25 JP JP2024009496A patent/JP2024056735A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200124709A (ko) | 2020-11-03 |
| EA202092000A1 (ru) | 2020-12-09 |
| US20200377503A1 (en) | 2020-12-03 |
| WO2019165358A1 (en) | 2019-08-29 |
| AU2019223168A1 (en) | 2020-09-10 |
| CN111886009A (zh) | 2020-11-03 |
| US20220340572A1 (en) | 2022-10-27 |
| EP3755323A1 (en) | 2020-12-30 |
| AU2019223168B2 (en) | 2024-09-12 |
| JP7497046B2 (ja) | 2024-06-10 |
| EP3755323A4 (en) | 2021-11-24 |
| JP2024056735A (ja) | 2024-04-23 |
| US11999731B2 (en) | 2024-06-04 |
| CA3091834A1 (en) | 2019-08-29 |
| MX2020008767A (es) | 2021-01-08 |
| US11358965B2 (en) | 2022-06-14 |
| KR102748047B1 (ko) | 2024-12-27 |
| JP2021514001A (ja) | 2021-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112020017184A2 (pt) | Disruptores de dímero egfr e uso dos mesmos | |
| US12310968B2 (en) | Chiral diaryl macrocycles and uses thereof | |
| ES2610226T3 (es) | Compuestos de 6-amino-piridazin-3-il-carboxamida sustituidos como moduladores de proteínas cinasas | |
| BR112020001695A2 (pt) | compostos macrocíclicos e usos dos mesmos | |
| KR20220050143A (ko) | Kras-관련 암 치료 방법 | |
| CN115397413A (zh) | Egfr、kras、braf和其他靶标的抑制剂及其用途 | |
| BR112016006692B1 (pt) | Composto derivado de quinazolina, composição farmacêutica e seus usos | |
| ES2670665T3 (es) | Compuestos de piridazina carboxamida sustituidos como compuestos inhibidores de quinasa | |
| CA2960971A1 (en) | Compounds and compositions as raf kinase inhibitors | |
| WO2024098001A1 (en) | Naphthyridone compounds for inhibition of raf kinases | |
| EA042609B1 (ru) | Ингибиторы димеризации egfr и их использование | |
| HK40034660A (en) | Egfr dimer disruptors and use of the same | |
| RU2774952C2 (ru) | Соединения | |
| WO2025101571A1 (en) | Tetrahydroisoquinoline heterobifunctional bcl-x l degraders | |
| BR112019011835B1 (pt) | Composto aminopirazol inibidor de janus quinase, composições farmacêuticas, e uso dos mesmos | |
| HK1263053A1 (en) | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] |